| 1 |
34871838 | The protective effects of Omarigliptin against Lipopolysaccharide (LPS)- induced inflammatory response and expression of mucin 5AC (MUC5AC) in human bronchial epithelial cells. | 2022 Jan |
2 |
| 2 |
33474645 | Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type 2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label, Multicenter Randomized Controlled Study. | 2021 Mar |
2 |
| 3 |
33512755 | A randomized, placebo-controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control. | 2021 Jun |
1 |
| 4 |
33691757 | Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. | 2021 Mar 10 |
3 |
| 5 |
34338149 | Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cells. | 2021 Dec |
2 |
| 6 |
34390762 | Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: A prospective study. | 2021 Sep |
1 |
| 7 |
32211075 | Omarigliptin decreases inflammation and insulin resistance in a pleiotropic manner in patients with type 2 diabetes. | 2020 |
2 |
| 8 |
31454094 | Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin. | 2019 Dec |
6 |
| 9 |
28665228 | Absorption, metabolism and excretion of [14C]omarigliptin, a once-weekly DPP-4 inhibitor, in humans. | 2018 Jun |
2 |
| 10 |
29079379 | A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes. | 2018 Apr |
1 |
| 11 |
30142816 | The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: A systemic review and meta-analysis. | 2018 Aug |
1 |
| 12 |
27182005 | Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men. | 2017 Jan |
3 |
| 13 |
28093853 | Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. | 2017 Mar |
1 |
| 14 |
28260743 | Pharmacological action and clinical results of Omarigliptin (MARIZEV® tablet), a novel dipeptidyl peptidase-4 inhibitor for once-weekly treatment of Type 2 diabetes. | 2017 |
1 |
| 15 |
28449320 | A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment. | 2017 Jun |
1 |
| 16 |
28449368 | A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes. | 2017 Nov |
1 |
| 17 |
28547998 | A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. | 2017 Oct |
1 |
| 18 |
28548024 | A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. | 2017 Oct |
1 |
| 19 |
28589493 | A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control. | 2017 Aug |
1 |
| 20 |
28776371 | Asymmetric Formal Synthesis of the Long-Acting DPP-4 Inhibitor Omarigliptin. | 2017 Sep 1 |
2 |
| 21 |
28883229 | Efficacy and Patient Satisfaction of the Weekly DPP-4 Inhibitors Trelagliptin and Omarigliptin in 80 Japanese Patients with Type 2 Diabetes. | 2017 Oct 1 |
1 |
| 22 |
28893244 | A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus. | 2017 Sep 11 |
1 |
| 23 |
28923291 | Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds. | 2017 Oct |
1 |
| 24 |
29110647 | A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin. | 2017 Nov 6 |
2 |
| 25 |
26869191 | Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus. | 2016 Mar |
2 |
| 26 |
27225334 | Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy Subjects. | 2016 Dec |
4 |
| 27 |
27372109 | Omarigliptin for the treatment of type 2 diabetes. | 2016 Oct |
2 |
| 28 |
27466703 | Omarigliptin for the treatment of type 2 diabetes mellitus. | 2016 Oct |
3 |
| 29 |
27627193 | Effects of Age, Sex, and Obesity on the Single-Dose Pharmacokinetics of Omarigliptin in Healthy Subjects. | 2016 Sep |
1 |
| 30 |
27627194 | A Thorough QTc Study Confirms Early Pharmacokinetics/QTc Modeling: A Supratherapeutic Dose of Omarigliptin, a Once-Weekly DPP-4 Inhibitor, Does Not Prolong the QTc Interval. | 2016 Sep |
1 |
| 31 |
26310692 | Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes. | 2015 Nov |
2 |
| 32 |
26507988 | Omarigliptin: first global approval. | 2015 Nov |
2 |
| 33 |
26546218 | Structure-activity-relationship of amide and sulfonamide analogs of omarigliptin. | 2015 Dec 15 |
2 |
| 34 |
24660890 | Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. | 2014 Apr 24 |
10 |